Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

SEQIRUS INC

UEI: Z6N1LJ2RD6E3CAGE: 7L0Y8

SEQIRUS INC is a federal contractor, registered under UEI Z6N1LJ2RD6E3 and CAGE code 7L0Y8. It has been awarded $1,911,344,400 in federal contracts. Primary work spans Industrial Building Construction, Biological Product (except Diagnostic) Manufacturing, and Research and Development in the Physical, Engineering, and Life Sciences. Top awarding agencies include Department Of Health And Human Services.

Contact Information

Registration and classification details

Registration

UEI Code

Z6N1LJ2RD6E3

CAGE Code

7L0Y8

Entity Structure

Corporate Entity (Not Tax Exempt)

Established

N/A

Business Classifications

For Profit OrganizationForeign OwnedManufacturer of Goods

NAICS Codes

325414Biological Product (except Diagnostic) Manufacturing(Primary)

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

AI Capability Profile

SEQIRUS INC specializes in the manufacturing and development of biological products, particularly vaccines and adjuvants for pandemic preparedness and public health emergency response. The company provides end-to-end capabilities in the production of influenza antigen monobulks, seed lot development...

SEQIRUS INC specializes in the manufacturing and development of biological products, particularly vaccines and adjuvants for pandemic preparedness and public health emergency response. The company provides end-to-end capabilities in the production of influenza antigen monobulks, seed lot development, and stability testing of biologics, with deep expertise in GMP-compliant manufacturing processes for medical countermeasures. Their technical focus includes physical and chemical compatibility studies, formulation validation, and resampling of legacy biological lots to support long-term storage and regulatory compliance. SEQIRUS demonstrates specialized proficiency in supporting HHS initiatives for H5N1, H5N8, and other pandemic influenza strains, integrating advanced bioprocessing techniques with rigorous quality control protocols to ensure product integrity under demanding storage and shelf-life requirements. The contractor maintains a consistent and exclusive relationship with the Department of Health and Human Services, delivering critical biological manufacturing and research services under IDIQ contracts for medical countermeasure acquisition and pandemic readiness. Their work directly supports HHS’s Biomedical Advanced Research and Development Authority (BARDA) objectives, focusing on scalable, timely production of vaccines and adjuvants for emerging infectious threats. SEQIRUS operates primarily within NAICS 325414, which encompasses the manufacturing of biological products excluding diagnostics, positioning them as a niche provider in the federal biodefense and public health supply chain. Their market focus is squarely on high-containment, regulated biologics manufacturing for government emergency response programs, with minimal diversification into other sectors. As a 2L entity headquartered in Holly Springs, NC, SEQIRUS operates as a specialized manufacturer without federal certifications such as 8(a), HUBZone, or SDVOSB. Their geographic presence is centered in North Carolina, leveraging regional biomanufacturing infrastructure to serve federal health security priorities with precision and regulatory fidelity.

Key Performance Metrics

Awards Count

47

All time

Active

8

Currently performing

Completed

39

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency
Awards by Agency Over Time
Awards by Place of Performance

Compete with SEQIRUS INC

Track the contractors you bid against, and the work they win

Award history, agency mix, and NAICS coverage for SEQIRUS INC

AI-powered matching against your own capabilities and past performance

Teaming and subcontracting signals on every award

Automated alerts when a competitor wins in your market

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS

Open opportunities in SEQIRUS INC's top NAICS codes and agencies

NAICS: 541714
New
Federal
AJ12--Development/Production - Kidney GEC-Specific AAV Vector
Solicitation # 36C24E27Q0009
The Department of Veterans Affairs is issuing a Sources Sought notice to identify capable vendors for the development and production of a kidney glomerular endothelial cell specific adeno-associated virus AAV vector. This project, funded by a VA ORD Merit award, aims to create a homing peptide enabled vector platform to target the glomerular endothelium to treat kidney injury and disease while reducing off target transduction. The scope of work is divided into three primary tasks: the engineering and incorporation of targeting peptides into the AAV capsid, testing vector binding and internalization in kidney tissue slices, and evaluating the specificity and efficiency of the modified vector through bioluminescence imaging and in vivo biodistribution studies. Qualified contractors must possess extensive onsite resources, including BSL 2 laboratories, specialized DNA and RNA facilities, and advanced instrumentation such as the Agilent Fragment Analyzer and various qPCR platforms. Vendors must demonstrate proven success in animal and human cell vector delivery and maintain full compliance with AAALAC and FELASA health standards. The government requires quarterly reporting, weekly videoconferences, and biannual face to face meetings. All generated data will be subject to Government Purpose Rights, and contractors must adhere to strict federal records management and information security protocols. Interested parties must submit a capability statement, relevant literature, and socio economic status details under NAICS 541714 by November 4, 2026.
Rpo East (36C24E)

POSTED

about 11 hours ago

DEADLINE

in 14 days
View Details
NAICS: 236210
New
Federal
IE181 - WHS Greenhouse Construction
Solicitation # 140A2327Q0297
Solicitation 140A2327Q0297 is a fixed-price contract set aside exclusively for Indian Small Business Economic Enterprises (ISBEE) to install a greenhouse at Wingate High School in Fort Wingate, New Mexico. The project, estimated between $100,000 and $250,000, involves a comprehensive scope of work including foundation construction, utility connections, glazing, environmental controls, and heating. The contractor must complete the installation within 120 calendar days from the Notice to Proceed, which is contingent upon the successful background investigation of on-site personnel. Required qualifications include New Mexico contractor licensure for general building, electrical, and mechanical/gas work, as well as any necessary Navajo Nation tribal business licenses. Award will be made using the Lowest Price Technically Acceptable (LPTA) method to a responsible offeror who meets all technical requirements, including the submission of a project-specific Quality Control Plan and a detailed progress schedule. Bids exceeding $35,000 require a bid bond. Offerors must be registered in SAM.gov and provide a signed quote, UEI number, and specific Indian Economic Enterprise representations. The project must adhere to strict safety and quality standards, including OSHA, NEC, IBC, and ASTM specifications, and comply with the Davis-Bacon Act for wage requirements. All quotes are due to the Bureau of Indian Education by November 19, 2026, at 12:00 PM MDT.
Indian Education Acquisition Office

POSTED

1 day ago

DEADLINE

in 29 days
View Details
NAICS: 541714
New
Grant
Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed)
Solicitation # RFA-AI-28-012
The National Institute of Allergy and Infectious Diseases (NIAID) has issued solicitation RFA-AI-28-012 to establish a consortium of Translational Centers Using Microphysiological Systems for Infectious Diseases (TCMID). The primary objective is to refine and validate human tissue models using Microphysiological Systems (MPS) to a level consistent with regulatory qualifications, thereby promoting their adoption by product developers and reducing reliance on laboratory animals. This initiative aligns with NIH and FDA guidance on New Approach Methodologies (NAMs) to accelerate the development of safer medical interventions by capturing human variability and patient-specific characteristics. The program is structured around an Administrative Core, a Qualification Core, and Scientific Cores, with a heavy emphasis on technical readiness, reproducibility, and regulatory acceptance. Key deliverables include the validation of assays for specific endpoints and the submission of regulatory packages. Applicants must be domestic entities, as foreign organizations and foreign subawards are strictly prohibited. Required personnel must possess deep expertise in infectious diseases, MPS platforms, bioinformatics, and FDA submission processes. Applications are due by January 29, 2027, and must be submitted via the NIH ASSIST system or approved institutional system-to-system solutions. Evaluation is based on an overall impact score considering the project's significance, the suitability of the investigators, and the quality of the institutional environment. Mandatory application components include a Data Management and Sharing Plan and a Benchmarks and Timeline PDF not exceeding six pages. Awardees must also adhere to strict cybersecurity incident reporting guidelines, notifying HHS within 48 hours of any discovery.
National Institutes Of Health

POSTED

2 days ago

DEADLINE

in 3 months
View Details
NAICS: 541714
New
Grant
Immune Tolerance Network (UM1 Clinical Trial Required)
Solicitation # RFA-AI-28-005
The National Institutes of Health, under the Department of Health and Human Services, is seeking applications through solicitation RFA-AI-28-005 to continue the Immune Tolerance Network (ITN). This cooperative agreement aims to develop tolerogenic therapies for immune-mediated disorders, specifically focusing on autoimmune diseases, allergic diseases and asthma, and the immune-mediated consequences of transplantation. The network operates through four integrated functional areas: Leadership, Clinical Operations, Core Laboratory, and Bioinformatics. Its primary objectives include designing and conducting clinical trials, performing integrated mechanistic studies, and sharing research results. Eligible applicants include small businesses and other for-profit organizations, though non-domestic entities are ineligible. Applications are evaluated based on scientific and technical merit, with a primary focus on significance and the likelihood of exerting a sustained influence on the research field. Key requirements include maintaining active registrations in SAM.gov, eRA Commons, and Grants.gov, as well as adhering to strict cybersecurity incident reporting and human subject protection protocols. The project requires a minimum effort of 3.6 person months per year for the PD/PI and mandates participation in a kick-off meeting in Bethesda, Maryland, and bi-annual steering meetings. Applications must follow specific page limits for the research strategy subsections and include detailed plans for clinical trial implementation, data management, and biorepository services.
National Institutes Of Health

POSTED

2 days ago

DEADLINE

in 3 months
View Details